Published in Ann Intern Med on February 03, 2009
Against diagnosis. Ann Intern Med (2008) 3.69
Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ (2003) 18.72
Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol (2005) 10.99
Screening for prostate cancer: systematic review and meta-analysis of randomised controlled trials. BMJ (2010) 7.15
Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials. Lancet (2009) 6.92
Stopping randomized trials early for benefit and estimation of treatment effects: systematic review and meta-regression analysis. JAMA (2010) 5.90
Red blood cell transfusion: a clinical practice guideline from the AABB*. Ann Intern Med (2012) 5.77
Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol (2006) 4.87
Recommendations on the use of 18F-FDG PET in oncology. J Nucl Med (2008) 4.71
Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. J Clin Oncol (2002) 4.69
Colony-stimulating factors for febrile neutropenia during cancer therapy. N Engl J Med (2013) 4.20
Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update. J Clin Oncol (2007) 3.85
Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst (2006) 3.23
Platelet transfusion: a clinical practice guideline from the AABB. Ann Intern Med (2014) 2.63
Tandem versus single autologous hematopoietic cell transplantation for the treatment of multiple myeloma: a systematic review and meta-analysis. J Natl Cancer Inst (2009) 2.46
Evaluation of new treatments in radiation oncology: are they better than standard treatments? JAMA (2005) 2.37
Preliminary evaluation of factors associated with premature trial closure and feasibility of accrual benchmarks in phase III oncology trials. Clin Trials (2010) 2.24
When to perform hepatic resection for intermediate-stage hepatocellular carcinoma. Hepatology (2015) 2.15
Colony-stimulating factors for chemotherapy-induced febrile neutropenia: a meta-analysis of randomized controlled trials. J Clin Oncol (2005) 2.13
Human recombinant erythropoietin and quality of life: a wonder drug or something to wonder about? Lancet Oncol (2002) 2.01
Randomized trials in oncology stopped early for benefit. J Clin Oncol (2008) 1.89
Treatment tolerance and efficacy in geriatric oncology: a systematic review of phase III randomized trials conducted by five National Cancer Institute-sponsored cooperative groups. J Clin Oncol (2007) 1.86
Itraconazole prevents invasive fungal infections in neutropenic patients treated for hematologic malignancies: evidence from a meta-analysis of 3,597 patients. J Clin Oncol (2003) 1.71
Prophylactic granulocyte colony-stimulating factor in patients receiving dose-intensive cancer chemotherapy: a meta-analysis. Am J Med (2002) 1.69
When is diagnostic testing inappropriate or irrational? Acceptable regret approach. Med Decis Making (2008) 1.62
Multiple myeloma. Clinical practice guidelines in oncology. J Natl Compr Canc Netw (2007) 1.53
Role of high-dose chemotherapy and autologous hematopoietic cell transplantation in primary systemic amyloidosis: a systematic review. Biol Blood Marrow Transplant (2009) 1.51
Placebo-controlled phase III trial of patient-specific immunotherapy with mitumprotimut-T and granulocyte-macrophage colony-stimulating factor after rituximab in patients with follicular lymphoma. J Clin Oncol (2009) 1.46
High-dose therapy with single autologous transplantation versus chemotherapy for newly diagnosed multiple myeloma: A systematic review and meta-analysis of randomized controlled trials. Biol Blood Marrow Transplant (2007) 1.45
NCCN clinical practice guidelines in oncology: multiple myeloma. J Natl Compr Canc Netw (2009) 1.44
Challenges to accrual predictions to phase III cancer clinical trials: a survey of study chairs and lead statisticians of 248 NCI-sponsored trials. Clin Trials (2011) 1.43
Achieving sufficient accrual to address the primary endpoint in phase III clinical trials from U.S. Cooperative Oncology Groups. Clin Cancer Res (2011) 1.42
Choosing a control intervention for a randomised clinical trial. BMC Med Res Methodol (2003) 1.41
Trial sequential analysis may be insufficient to draw firm conclusions regarding statistically significant treatment differences using observed intervention effects: a case study of meta-analyses of multiple myeloma trials. Contemp Clin Trials (2012) 1.40
Evidence profiles for colo-rectal cancer: benefit/harms data based on the totality of randomized evidence. Cancer Treat Rev (2006) 1.40
Efficacy of rituximab in the setting of steroid-refractory chronic graft-versus-host disease: a systematic review and meta-analysis. Biol Blood Marrow Transplant (2009) 1.40
Lifting the fog of uncertainty from the practice of medicine. BMJ (2004) 1.35
Evaluation of serious adverse drug reactions: a proactive pharmacovigilance program (RADAR) vs safety activities conducted by the Food and Drug Administration and pharmaceutical manufacturers. Arch Intern Med (2007) 1.34
Improving the efficiency and relevance of evidence-based recommendations in the era of whole-genome sequencing: an EGAPP methods update. Genet Med (2012) 1.34
Published methodological quality of randomized controlled trials does not reflect the actual quality assessed in protocols. J Clin Epidemiol (2012) 1.32
Multiple myeloma. J Natl Compr Canc Netw (2011) 1.28
Erythropoietin or Darbepoetin for patients with cancer--meta-analysis based on individual patient data. Cochrane Database Syst Rev (2009) 1.26
A systematic review of quality of life associated with standard chemotherapy regimens for advanced non-small cell lung cancer. J Thorac Oncol (2007) 1.25
A regret theory approach to decision curve analysis: a novel method for eliciting decision makers' preferences and decision-making. BMC Med Inform Decis Mak (2010) 1.23
Bisphosphonates in multiple myeloma: a network meta-analysis. Cochrane Database Syst Rev (2012) 1.16
Adherence to antiretroviral therapy in India: a systematic review and meta-analysis. Indian J Community Med (2013) 1.16
Multiple myeloma, version 1.2013. J Natl Compr Canc Netw (2013) 1.14
Cancer- and chemotherapy-induced anemia. J Natl Compr Canc Netw (2012) 1.10
Decision analysis of peripheral blood versus bone marrow hematopoietic stem cells for allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant (2009) 1.09
Management of multiple myeloma: a systematic review and critical appraisal of published studies. Lancet Oncol (2003) 1.08
Quality and methods of developing practice guidelines. BMC Health Serv Res (2002) 1.06
Survival of patients with non-small cell lung cancer without treatment: a systematic review and meta-analysis. Syst Rev (2013) 1.03
Thalidomide versus bortezomib based regimens as first-line therapy for patients with multiple myeloma: a systematic review. Am J Hematol (2011) 1.01
Acting on imperfect evidence: How much regret are we ready to accept? J Clin Oncol (2005) 0.99
Comparator bias: why comparisons must address genuine uncertainties. J R Soc Med (2013) 0.99
Systematic review of piperacillin-induced neutropenia. Drug Saf (2007) 0.97
Quality of reporting of serious adverse drug events to an institutional review board: a case study with the novel cancer agent, imatinib mesylate. Clin Cancer Res (2009) 0.96
Evidence-based medicine for rare diseases: implications for data interpretation and clinical trial design. Cancer Control (2007) 0.96
Erythropoietin, uncertainty principle and cancer related anaemia. BMC Cancer (2002) 0.96
The sound and the fury: financial conflicts of interest in oncology. J Clin Oncol (2007) 0.96
Extensions to regret-based decision curve analysis: an application to hospice referral for terminal patients. BMC Med Inform Decis Mak (2011) 0.95
Comparative efficacy of tandem autologous versus autologous followed by allogeneic hematopoietic cell transplantation in patients with newly diagnosed multiple myeloma: a systematic review and meta-analysis of randomized controlled trials. J Hematol Oncol (2013) 0.95
Allogeneic hematopoietic cell transplantation for adult acute lymphoblastic leukemia (ALL) in first complete remission. Cochrane Database Syst Rev (2011) 0.94
Gemtuzumab ozogamicin for treatment of newly diagnosed acute myeloid leukaemia: a systematic review and meta-analysis. Br J Haematol (2013) 0.93
The Australian 'FORM' approach to guideline development: the quest for the perfect system. BMC Med Res Methodol (2011) 0.93
Efficacy of adoptive immunotherapy with donor lymphocyte infusion in relapsed lymphoid malignancies. Immunotherapy (2013) 0.92
Decision-making when data and inferences are not conclusive: risk-benefit and acceptable regret approach. Semin Hematol (2008) 0.91
Stopping randomized trials early for benefit: a protocol of the Study Of Trial Policy Of Interim Truncation-2 (STOPIT-2). Trials (2009) 0.89
Waldenström's macroglobulinemia/lymphoplasmacytic lymphoma, version 2.2013. J Natl Compr Canc Netw (2012) 0.89
Bisphosphonates in multiple myeloma. Cochrane Database Syst Rev (2010) 0.89
Colony-stimulating factors for chemotherapy-induced febrile neutropenia. Cochrane Database Syst Rev (2014) 0.88
A systematic review and lessons learned from early lung cancer detection trials using low-dose computed tomography of the chest. Cancer Control (2003) 0.88
High-dose chemotherapy followed by autologous stem cell transplantation as first-line therapy in aggressive non-Hodgkin's lymphoma: a meta-analysis. Haematologica (2003) 0.87
Oncology treatment recommendations can be supported only by 1-2% of high-quality published evidence. Cancer Treat Rev (2005) 0.86
Association between competing interests and conclusions. Denominator problem needs to be addressed. BMJ (2002) 0.85
Implications of the principle of question propagation for comparative-effectiveness and "data mining" research. JAMA (2011) 0.84
Cancer- and chemotherapy-induced anemia. J Natl Compr Canc Netw (2008) 0.84
Comparative efficacy of first-line therapies for advanced-stage chronic lymphocytic leukemia: a multiple-treatment meta-analysis. Cancer Treat Rev (2012) 0.83
Multiple Myeloma, Version 2.2016. J Natl Compr Canc Netw (2015) 0.81
Optimal type I and type II error pairs when the available sample size is fixed. J Clin Epidemiol (2013) 0.81
Mycophenolate mofetil versus methotrexate for prevention of graft-versus-host disease in people receiving allogeneic hematopoietic stem cell transplantation. Cochrane Database Syst Rev (2014) 0.81
The challenge of systematic reviews of diagnostic and staging studies in cancer. Cancer Treat Rev (2005) 0.81
Myeloma (multiple). Clin Evid (2006) 0.81
Treatment of patients with multiple myeloma: an overview of systematic reviews. Acta Haematol (2010) 0.80
Decitabine versus 5-azacitidine for the treatment of myelodysplastic syndrome: adjusted indirect meta-analysis. Haematologica (2009) 0.80
What does randomisation achieve? Evid Based Med (2011) 0.79
The role of iron in the management of chemotherapy-induced anemia in cancer patients receiving erythropoiesis-stimulating agents. Cochrane Database Syst Rev (2016) 0.79
Cancer- and treatment-related anemia. J Natl Compr Canc Netw (2005) 0.79
JAMA published fewer industry-funded studies after introducing a requirement for independent statistical analysis. PLoS One (2010) 0.79
Value of repeat head computed tomography after traumatic brain injury: systematic review and meta-analysis. J Neurotrauma (2013) 0.79
Misconceptions, challenges, uncertainty, and progress in guideline recommendations. Semin Hematol (2008) 0.79
Defining optimum treatment of patients with pancreatic adenocarcinoma using regret-based decision curve analysis. Ann Surg (2014) 0.79
Failure of equipoise to resolve the ethical tension in a randomized clinical trial. J Law Med Ethics (2003) 0.79
Identifying homogenous subgroups for individual patient meta-analysis based on Rough Set Theory. Conf Proc IEEE Eng Med Biol Soc (2014) 0.78
Clinical equipoise and the therapeutic misconception. Hastings Cent Rep (2003) 0.78